No headlines found.
PRNewswire (Tue, 23-Apr 10:57 AM ET)
PRNewswire (Mon, 18-Mar 7:01 AM ET)
PRNewswire (Mon, 4-Mar 7:01 AM ET)
PRNewswire (Tue, 27-Feb 7:01 AM ET)
Globe Newswire (Fri, 23-Feb 9:30 AM ET)
Globe Newswire (Fri, 16-Feb 9:30 AM ET)
Globe Newswire (Fri, 2-Feb 9:30 AM ET)
Globe Newswire (Thu, 1-Feb 9:33 AM ET)
PRNewswire (Mon, 29-Jan 7:00 AM ET)
Globe Newswire (Fri, 26-Jan 10:55 AM ET)
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Acurx Pharmaceuticals trades on the NASDAQ stock market under the symbol ACXP.
As of April 24, 2024, ACXP stock price declined to $1.97 with 4,123 million shares trading.
ACXP has a beta of -2.66, meaning it tends to be less sensitive to market movements. ACXP has a correlation of 0.07 to the broad based SPY ETF.
ACXP has a market cap of $31.04 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that ACXP belongs to (by Net Assets): VTI, VXF, IWC.
ACXP has underperformed the market in the last year with a return of -34.8%, while the SPY ETF gained +24.5%. In the last 3 month period, ACXP fell short of the market, returning -47.9%, while SPY returned +4.7%. However, in the most recent 2 weeks ACXP has outperformed the stock market by returning +2.1%, while SPY returned -2.5%.
ACXP support price is $1.90 and resistance is $2.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACXP stock will trade within this expected range on the day.